Ajanta Pharma Limited (NSE:AJANTPHARM)
2,585.20
-120.90 (-4.47%)
May 2, 2025, 3:29 PM IST
Ajanta Pharma Revenue
In the fiscal year ending March 31, 2025, Ajanta Pharma had annual revenue of 46.48B INR with 10.44% growth. Ajanta Pharma had revenue of 11.70B in the quarter ending March 31, 2025, with 11.04% growth.
Revenue
46.48B
Revenue Growth
+10.44%
P/S Ratio
6.95
Revenue / Employee
5.76M
Employees
8,073
Market Cap
322.86B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 46.48B | 4.39B | 10.44% |
Mar 31, 2024 | 42.09B | 4.66B | 12.45% |
Mar 31, 2023 | 37.43B | 4.02B | 12.02% |
Mar 31, 2022 | 33.41B | 4.51B | 15.62% |
Mar 31, 2021 | 28.90B | 3.02B | 11.66% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 516.03B |
Divi's Laboratories | 90.78B |
Cipla | 267.20B |
Mankind Pharma | 116.41B |
Apollo Hospitals Enterprise | 211.46B |
Zydus Lifesciences | 222.47B |
Aurobindo Pharma | 309.22B |
Alkem Laboratories | 127.57B |
Ajanta Pharma News
- 2 days ago - Ajanta Pharma Q4 Results: Net profit grows 11% YoY to Rs 225 crore, EBITDA Margin at 25% - Business Upturn
- 18 days ago - Stocks to buy today on brokerages’ call: IndiGo, Ajanta Pharma, TBO, HDFC Bank, Vodafone Idea among top picks – Check investment target - Business Upturn
- 18 days ago - Jefferies initiates Buy on Ajanta Pharma, sees 11% upside due to strong presence in branded generics markets - Business Upturn
- 18 days ago - Stocks to watch today: Interglobe Aviation, Ajanta Pharma, HDFC Bank, Vodafone Idea, Hindalco, TBO, L&T in focus on brokerage reports - Business Upturn
- 3 months ago - Ajanta Pharma Q3FY25 results: Revenue rises 4% YoY to Rs 1,146 crore, PAT Up 11% to Rs 233 crore - Business Upturn
- 5 months ago - Pharma Stocks: Cipla down nearly 2%, Ajanta Pharma down 1.45%, Abbott India up 1.27% - Business Upturn
- 6 months ago - Ajanta Pharma declares first interim dividend of ₹28 per share for FY25 - Business Upturn
- 6 months ago - Ajanta Pharma Q2 FY25 Results: Revenue rises 15% to ₹1,187 crore, net profit grows 11% to ₹216 crore - Business Upturn